Hypofractionation (Radiation) Trial for Multiple Myeloma - Trial NCT06270888
Access comprehensive clinical trial information for NCT06270888 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Chicago and is currently Not yet recruiting. The study focuses on Multiple Myeloma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Chicago
Timeline & Enrollment
Phase 1
May 01, 2024
May 01, 2028
Primary Outcome
Maximum Tolerated Dose of Radiation of Per Fraction
Summary
This study if for people who have been diagnosed with multiple myeloma and their doctors are
 recommending radiation to help treat it. Typically, radiation consists of 2-3 weeks of
 external beam radiation therapy. Doctors leading this study would like to see if a shorter
 radiation course (i.e., hypofractionation) for pelvic radiation is safe for multiple myeloma.
 Because participants in this study will receive a shortened radiation course, each daily
 treatment dose that is delivered would be slightly higher than normal. This higher daily dose
 would be delivered because the study team would like to see if higher doses of radiation are
 as safe given over a shorter number of days compared to 2-3 weeks. The purpose of this study
 is to make sure that hypofractionation is safe and effective for individuals with multiple
 myeloma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06270888
Non-Device Trial